CVS Health (NYSE:CVS) Stock Price Target Lowered at Wells Fargo & Company

CVS Health (NYSE:CVS) had its target price cut by investment analysts at Wells Fargo & Company from $123.00 to $112.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the pharmacy operator’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 25.23% from the company’s current price.

Several other analysts also recently weighed in on the stock. Piper Sandler set a $112.00 target price on shares of CVS Health in a research report on Wednesday, September 9th. Raymond James Financial set a $103.00 price target on shares of CVS Health in a report on Friday, November 6th. TD Cowen reiterated a “buy” rating on shares of CVS Health in a research note on Wednesday, November 4th. Barclays dropped their price objective on shares of CVS Health from $108.00 to $107.00 and set an “overweight” rating on the stock in a report on Thursday, November 5th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $103.00 target price on shares of CVS Health in a research report on Wednesday, November 4th. Twenty-three investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and an average target price of $107.79.

CVS Health Price Performance

Shares of NYSE CVS opened at $89.43 on Thursday. CVS Health has a fifty-two week low of $69.51 and a fifty-two week high of $110.68. The company has a market cap of $114.43 billion, a PE ratio of 10.41, a P/E/G ratio of 0.77 and a beta of 0.58. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.66 and a current ratio of 0.85. The business has a 50-day simple moving average of $89.96 and a two-hundred day simple moving average of $88.97.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, November 4th. The pharmacy operator reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.65 by $0.44. The firm had revenue of $108.40 billion for the quarter, compared to the consensus estimate of $104.72 billion. CVS Health had a net margin of 2.62% and a return on equity of 13.65%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.60 earnings per share. As a group, equities analysts expect that CVS Health will post 8.26 EPS for the current fiscal year.

Insider Activity

In related news, EVP Prem Shah bought 23,855 shares of the stock in a transaction dated Friday, November 6th. The shares were purchased at an average price of $83.89 per share, for a total transaction of $2,001,195.95. Following the completion of the purchase, the executive vice president directly owned 88,516 shares of the company’s stock, valued at $7,425,607.24. This represents a 36.89% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.85% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Kilter Group LLC acquired a new position in CVS Health in the second quarter valued at approximately $27,000. Beaird Harris Wealth Management LLC grew its stake in shares of CVS Health by 201.0% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock worth $30,000 after purchasing an additional 195 shares during the period. J.Safra Asset Management Corp acquired a new stake in shares of CVS Health during the 2nd quarter worth approximately $30,000. Timbuktu Capital Management LLC purchased a new position in shares of CVS Health during the 2nd quarter valued at approximately $31,000. Finally, Dunhill Financial LLC purchased a new position in shares of CVS Health during the 2nd quarter valued at approximately $32,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Key CVS Health News

Here’s some of the latest news about CVS:

• Positive Sentiment: The planned 2028 separation could give the businesses sharper strategic focus and improve capital allocation, with the potential to unlock value if CVS executes successfully. Can CVS Health’s 2028 Split Unlock Value Despite Execution Risks?
• Neutral Sentiment: CVS is accelerating coverage of lower-cost Humira and Stelara biosimilars through Caremark. This may help manage drug costs, though the financial impact is not yet clear. What Is CVS Health Signaling With Its Faster Biosimilar Push?
• Negative Sentiment: Investors also face ongoing PBM pressures and membership declines. One recent valuation update modestly lowered its fair-value estimate, reflecting separation risks and analyst caution. Is CVS Stock Worth Buying as Aetna Recovers but PBM Risks Persist?

CVS Health Company Profile

CVS Health is a U.S.-based health care company that operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance and other health services. Its businesses include CVS Pharmacy, pharmacy benefit manager CVS Caremark, and Aetna, its health benefits division. The company also provides care through MinuteClinic walk-in clinics and health care businesses including Oak Street Health and Signify Health. Its services span prescription fulfillment, pharmacy benefit management, health insurance, primary care, and in-home and community-based care.